About this trial
This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.
BACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.
OBJECTIVES:
Primary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model
DESIGN: Mixed retrospective-prospective cohort study
* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024 * Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028
SETTING: Single tertiary referral center with \>10,000 endoscopic polyp resections performed since 2021
PARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps
FOLLOW-UP:
* Short-term: 1 year post-resection (±2 months) * Long-term: 3 years post-resection (±3 months)
MAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance
POTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use
EXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.
Eligibility criteria
Qualifiers
Age 18 years or older
First-time endoscopic examination (gastroscopy or colonoscopy) at the study center
Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)
Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)
Disqualifiers
Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)
Inflammatory bowel disease (ulcerative colitis or Crohn's disease)
Previous history of gastric or colorectal cancer
Cancer detected at initial resection (stage T1b or higher)
Trial design
Treatments tested in this trial
- Not listed